NASDAQ:VALN Valneva (VALN) Stock Price, News & Analysis $4.43 +0.01 (+0.23%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Valneva Stock (NASDAQ:VALN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Valneva alerts:Sign Up Key Stats Today's Range$4.29▼$4.5650-Day Range$4.42▼$6.2952-Week Range$4.27▼$11.96Volume10,441 shsAverage Volume25,413 shsMarket Capitalization$359.94 millionP/E RatioN/ADividend YieldN/APrice Target$18.50Consensus RatingBuy Company OverviewValneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.Read More… Coins Set to Soar with a Pro-Crypto White House (Ad)Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…Click here to reserve your free seat at the Crypto Community Summit Valneva Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreVALN MarketRank™: Valneva scored higher than 47% of companies evaluated by MarketBeat, and ranked 626th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingValneva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageValneva has only been the subject of 1 research reports in the past 90 days.Read more about Valneva's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Valneva are expected to decrease in the coming year, from $0.15 to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Valneva is -34.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Valneva is -34.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioValneva has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Valneva's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.06% of the float of Valneva has been sold short.Short Interest Ratio / Days to CoverValneva has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Valneva has recently decreased by 12.68%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldValneva does not currently pay a dividend.Dividend GrowthValneva does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.06% of the float of Valneva has been sold short.Short Interest Ratio / Days to CoverValneva has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Valneva has recently decreased by 12.68%, indicating that investor sentiment is improving significantly. News and Social Media1.3 / 5News Sentiment0.29 News SentimentValneva has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Valneva this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 1 people have added Valneva to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Valneva insiders have not sold or bought any company stock.Percentage Held by Insiders14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.39% of the stock of Valneva is held by institutions.Read more about Valneva's insider trading history. Receive VALN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter. Email Address VALN Stock News HeadlinesWhat you need to know about the new Chikungunya vaccine and where to get it in B.C.November 18, 2024 | msn.comFinancial Contrast: Relay Therapeutics (NASDAQ:RLAY) vs. Valneva (NASDAQ:VALN)November 18, 2024 | americanbankingnews.comLet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! November 24, 2024 | DTI (Ad)European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health DepartmentNovember 16, 2024 | msn.comFrance stocks lower at close of trade; CAC 40 down 0.14%November 14, 2024 | msn.comValneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2November 13, 2024 | globenewswire.comValneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare ConferencesNovember 12, 2024 | markets.businessinsider.comKepler Capital Remains a Buy on Valneva (0OB3)November 10, 2024 | markets.businessinsider.comSee More Headlines VALN Stock Analysis - Frequently Asked Questions How have VALN shares performed this year? Valneva's stock was trading at $10.37 at the start of the year. Since then, VALN shares have decreased by 57.3% and is now trading at $4.43. View the best growth stocks for 2024 here. When did Valneva IPO? Valneva (VALN) raised $99 million in an initial public offering (IPO) on Thursday, May 6th 2021. The company issued 3,500,000 shares at $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as the underwriters for the IPO. Who are Valneva's major shareholders? Top institutional shareholders of Valneva include AlphaCentric Advisors LLC (0.15%). How do I buy shares of Valneva? Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Valneva own? Based on aggregate information from My MarketBeat watchlists, some other companies that Valneva investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Company Calendar Today11/24/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/19/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VALN CUSIPN/A CIK1836564 Webvalneva.com Phone33-2-28-07-37-10FaxN/AEmployees700Year FoundedN/APrice Target and Rating Average Stock Price Target$18.50 High Stock Price Target$20.00 Low Stock Price Target$17.00 Potential Upside/Downside+317.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E Ratio29.53 P/E GrowthN/ANet Income$-109,780,000.00 Net Margins-4.35% Pretax MarginN/A Return on Equity-3.93% Return on Assets-1.42% Debt Debt-to-Equity Ratio0.70 Current Ratio2.78 Quick Ratio2.25 Sales & Book Value Annual Sales$165.52 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$2.94 per share Price / Book1.51Miscellaneous Outstanding Shares81,250,000Free Float69,133,000Market Cap$359.94 million OptionableNot Optionable Beta2.17 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:VALN) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.